TSS
VRTX icon

Two Sigma Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Two Sigma Securities’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,500
Closed -$2.09M – 3283
2024
Q3 		$2.09M Sell
4,500
-4,000
-47% -$1.92M 0.04% 526
2024
Q2 		$3.98M Sell
8,500
-1,100
-11% -$477K 0.05% 423
2024
Q1 		$4.01M Buy
9,600
+2,400
+33% +$1.01M 0.04% 475
2023
Q4 		$2.93M Sell
7,200
-5,700
-44% -$2.11M 0.03% 541
2023
Q3 		$4.49M Buy
12,900
+9,400
+269% +$3.29M 0.05% 398
2023
Q2 		$1.23M Buy
3,500
+800
+30% +$270K 0.02% 844
2023
Q1 		$851K Sell
2,700
-3,300
-55% -$990K 0.02% 925
2022
Q4 		$1.73M Buy
6,000
+3,700
+161% +$1.13M 0.05% 462
2022
Q3 		$666K Buy
+2,300
New +$662K 0.02% 877
2022
Q1 		– Sell
-8,700
Closed -$1.91M – 2546
2021
Q4 		$1.91M Buy
+8,700
New +$1.69M 0.08% 129
2021
Q3 		– Sell
-1,500
Closed -$302K – 1995
2021
Q2 		$302K Buy
+1,500
New +$314K 0.01% 977
2021
Q1 		– Sell
-3,100
Closed -$733K – 1786
2020
Q4 		$733K Buy
3,100
+900
+41% +$206K 0.02% 510
2020
Q3 		$599K Sell
2,200
-600
-21% -$166K 0.01% 520
2020
Q2 		$813K Buy
2,800
+1,000
+56% +$271K 0.02% 463
2020
Q1 		$428K Sell
1,800
-8,300
-82% -$1.9M 0.01% 687
2019
Q4 		$2.21M Buy
10,100
+4,600
+84% +$931K 0.01% 701
2019
Q3 		$932K Buy
5,500
+2,100
+62% +$372K 0.01% 905
2019
Q2 		$623K Buy
3,400
+2,000
+143% +$350K 0.01% 975
2019
Q1 		$258K Sell
1,400
-6,300
-82% -$1.16M ﹤0.01% 1293
2018
Q4 		$1.28M Sell
7,700
-14,000
-65% -$2.43M 0.02% 535
2018
Q3 		$4.18M Sell
21,700
-11,100
-34% -$1.98M 0.03% 432
2018
Q2 		$5.58M Buy
32,800
+27,200
+486% +$4.22M 0.03% 467
2018
Q1 		$913K Buy
+5,600
New +$915K 0.01% 1315

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Two Sigma Securities's VRTX Position: Q1 2026 in Review

Two Sigma Securities opened a new position in Vertex Pharmaceuticals (VRTX) in Q1 2026: 587 shares worth $262K. The stake represents 0.03% of the portfolio and ranks #867 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in VRTX as recently as Q2 2025.

Two Sigma Securities first reported a position in VRTX in Q1 2016 and has held it in 27 quarters since. The position peaked at $14.6M in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Two Sigma Securities held 587 shares of Vertex Pharmaceuticals worth $262K as of Q1 2026.
  • Vertex Pharmaceuticals was a new Two Sigma Securities position in Q1 2026.
  • Vertex Pharmaceuticals made up 0.03% of Two Sigma Securities's portfolio in Q1 2026, its #867 holding.
  • Two Sigma Securities first reported a position in Vertex Pharmaceuticals in Q1 2016 and has held it in 27 quarters since.
  • Two Sigma Securities's Vertex Pharmaceuticals position peaked at $14.6M in Q4 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.